紫杉醇加顺铂治疗晚期非小细胞肺癌的临床疗效  

A clinical study on paclitaxel plus cisplatin combined therapy in the treatment of non-small cell lung cancer

作　　者：陈阵[1] 王哲海[1] 李长征[1] 

机构地区：[1]山东省肿瘤医院内科,济南250117

出　　处：《中国肺癌杂志》2003年第5期386-387,共2页Chinese Journal of Lung Cancer

摘　　要：目的　观察紫杉醇 (PTX)加顺铂 (DDP)联合化疗治疗晚期非小细胞肺癌的近期疗效。方法　PTX 13 5～ 180mg/m2 静脉滴注 ,第 1天 ;DDP 40mg/次 ,静脉滴注 ,第 1～ 3天。每 2 1天为一个周期 ,连用 2或 3周期。结果　可评价疗效者 46例 ,其中CR 1例 ( 2 .2 % ) ,PR 16例 ( 3 4.8% ) ,总有效率为 3 7.0 %。毒副反应主要是骨髓抑制和恶心呕吐。结论　PTX +DDP治疗晚期非小细胞肺癌可获得较高疗效 ,毒副反应轻 。Objective To evaluate the results of combined chemotherapy with paclitaxel (PTX, taxol) plus cisplatin (DDP) in the treatment of advanced non small cell lung cancer (NSCLC). Methods From January 1997 to December 2002, forty seven patients with advanced non small cell lung cancer received PTX 135 180 mg/m 2 by intravenous infusion, on day 1, and DDP 40 mg/time by intravenous infusion,on days 1 3. The treatment was repeated every 3 weeks, up to 2 or 3 cycles. Results Forty six patients were evaluable for efficacy. One patient got complete response (2.2%), and 16 got partial response (34.8%), with an overall response rate of 37.0%. The main toxicities were myelosuppression, nausea and vomiting, and other side effects were mild. Conclusion A high response rate can be obtained in advanced NSCLC by PTX plus DDP. PTX is a promising antitumor agent with tolerable toxicity.

关 键 词：紫杉醇 顺铂 非小细胞肺痛 PTX DDP 治疗 化疔 毒副反应 

分 类 号：R734.2[医药卫生—肿瘤]